Advice

following a full submission:

glecaprevir-pibrentasvir (Maviret®) is accepted for use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults.

Glecaprevir-pibrentasvir is associated with high rates of sustained virologic suppression in patients with all genotypes of chronic HCV infection. In treatment-naïve non-cirrhotic patients with genotype 3 infection it was non-inferior to a direct acting anti-viral regimen that included a non-structural protein 5B (NS5B) inhibitor plus NS5A inhibitor.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir-pibrentasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Download detailed advice380KB (PDF)

Download

Medicine details

Medicine name:
glecaprevir/pibrentasvir (Maviret)
SMC ID:
1278/17
Indication:
Treatment of chronic hepatitis C virus (HCV) infection in adults.
Pharmaceutical company
AbbVie Ltd
BNF chapter
Infections
Submission type
Full
Status
Accepted
Date advice published:
13 November 2017